Mineralys Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MINERALYS THERAPEUTICS, INC. | |||
| Date: | March 21, 2024 | By: | /s/ Jon Congleton |
|---|---|---|---|
| Jon Congleton | |||
| Chief Executive Officer | |||
– 111 –
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons in the capacities held on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Jon Congleton | Chief Executive Officer (principal executive officer) | March 21, 2024 |
| Jon Congleton | ||
| /s/ Adam Levy | Chief Financial Officer and Secretary(principal financial and accounting officer) | March 21, 2024 |
| Adam Levy | ||
| /s/ Brian Taylor Slingsby | Executive Chairman | March 21, 2024 |
| Brian Taylor Slingsby, M.D., Ph.D., M.P.H. | ||
| /s/ Srinivas Akkaraju | Director | March 21, 2024 |
| Srinivas Akkaraju, M.D., Ph.D. | ||
| /s/ Alexander Asam | Director | March 21, 2024 |
| Alexander Asam, Ph.D. | ||
| /s/ Derek DiRocco | Director | March 21, 2024 |
| Derek DiRocco, Ph.D. | ||
| /s/ Olivier Litzka | Director | March 21, 2024 |
| Olivier Litzka, Ph.D. | ||
| /s/ Daphne Karydas | Director | March 21, 2024 |
| Daphne Karydas | ||
| /s/ Glenn Sblendorio | Director | March 21, 2024 |
| Glenn Sblendorio | ||
– 112 –
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.